ATHE | tickerfilter.com

Fundamental analysis

31%

Profitability 0%

Dept financing 18%

Liquidity 50%

Performance 60%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.86%

1 Month

39.56%

3 Months

25.64%

6 Months

-2.15%

1 Year

26.72%

2 Year

100.91%

Key data

Stock price

$4.41

P/E Ratio

0.00

DAY RANGE

$4.30 - $4.70

EPS

N/A

52 WEEK RANGE

$2.66 - $7.00

52 WEEK CHANGE

$26.72

MARKET CAP

73.604 M

YIELD

N/A

SHARES OUTSTANDING

8.867 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.82

PUBLIC FLOAT

AVERAGE 10 VOLUME

$41,698

AVERAGE 30 VOLUME

$23,892

Company detail

CEO: David A. Stamler
Region: US
Website: alteritytherapeutics.com
Employees: 10
IPO year: 2003

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's Disease.

ATHE - ALTERITY THERAPEUTICS LTD